HALT-IT trial, Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial
The HALT‐IT trial will determine the effect of early administration of TXA on mortality, morbidity (re‐bleeding, non‐fatal vascular events), blood transfusion, surgical intervention and health status in patients with acute gastrointestinal bleeding.
A pragmatic, randomised, double blind, placebo controlled trial among 8,000 patients with significant gastrointestinal bleeding.
Patients with significant GI bleeds in whom the use of tranexamic acid is neither indicated nor contraindicated
Professor Iain Roberts (LSHTM)
Dr Matt Reed (RIE)
Dr Nick Church
Dr James Dear
Dr Kallirroi Kefala
Julia Grahamslaw – local EMeRGE study lead
ED research nurses
The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme
Developing a bioresource for all emergency presentations
The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.
A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose
Patients commonly present to the Emergency Department with epistaxsis (nose bleed). Standard first aid measures such as applying pressure can often stem bleeding however in more severe cases of epistaxsis further treatment is required.
Novel Use of Tranexamic Acid to Reduce the Need for Nasal Packing